The NAD(P)H: Quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer

Chinese Journal of Medical Genetics

Volumn 20, Issue 6, 2003, Pages 544-546

  Zhang, Jian Hui ^a   Li, Yan ^a   Wang, Rui ^b   Mario, Sarbia ^c   Guo, Wei ^a   Wen, Deng Gui ^a   Wei, Li Zhen ^a   Chen, Zhi Feng ^a   Kuang, Gang ^a   Zhang, Li Wei ^b   He, Ming ^b   Wu, Ming Li ^b   Wang, Shi Jie ^b  

^a Hebei Cancer Institute   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Esophageal cancer; Genetic susceptibility; NAD(P)H:quinone oxidoreductase 1

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC;

EID: 9144242177     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kuehl BL, Paterson JW, Peacock JW, et al. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer, 1995, 72: 555-561.
2. Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci U S A, 1999, 96: 8150-8155.
3. Schulz WA, Krummeck A, Rosinger I, et al. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 1997, 7: 235-239.
4. Xu LL, Wain JC, Miller DP, et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on the smoking behavior. Cancer Epidemiol Biomarkers Prev, 2001, 10: 303-309.
5. 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 1999, 94: 803-807.
6. Wiemels JL, Pagnamenta A, Taylor GM, et al. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom childhood cancer study investigators. Cancer Res, 1999, 59: 4095-4099.
7. Miller SA, Dybes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res, 1988, 16: 1215.
8. Eickelmann P, Schulz WA, Rohde D, et al. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler, 1994, 375: 439-445.
9. Siegel D, Anwar A, Winski SL, et al. Rapid polyubiquination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol, 2001, 59: 263-268.